Co-founded by Yotam Hod, Gynica is an Israeli biotech company that is changing the future of women’s health by developing safe, effective, controlled-release treatments for Endometriosis and its main associated symptoms – severe menstrual pain and painful intercourse.
Endometriosis is a chronic debilitating disease that affects approximately 10% of women worldwide, approximately 200 million women and girls of reproductive age. This condition occurs when tissue similar to the lining of the uterus grows outside the uterus, causing a range of symptoms such as severe menstrual pain, digestive system disorders, extreme pain during sexual intercourse, abdominal pain, and infertility.
As an R&D company, Gynica has developed a proprietary product line (IntraVag©) which stands out as a non-hormonal and non-invasive treatment option with extended relief and minimal systemic absorption.
The entrance of Gilda D’Incerti in Gynica Advisory Board reflects PQE Group’s attitude and interest in developing innovative treatments and solutions to improve patients’ lives.
Yotam Hod, CEO & Co-Founder of Gynica:
“We are delighted to have Gilda D’Incerti join our advisory board at Gynica. Her extensive experience in the pharmaceutical and life sciences industries, particularly in navigating with the FDA and other regulatory agencies, will be immensely valuable as we pursue our goal of becoming a global leader in women’s health. We are confident that together we can drive innovation and make a meaningful difference for the millions of women worldwide who are impacted by Endometriosis and its related symptoms.”
Gilda D’Incerti CEO & Founder of PQE Group, member of Gynica Advisory Board:
“I’m very pleased to join the Advisory Board of Gynica, a young company that already has a strong impact on patients’ lives. Their products will shape the future of women’s health and are perfectly aligned with PQE Group and my personal vision: making an impact through the business.
Furthermore Gynica embodies the innovative soul that PQE Group promotes and invests in. We are confident that such collaboration and the future development of this and other products will bring meaningful results for all the women affected by Endometriosis and other diseases.”